A case of cystitis after administration of nivolumab
A case of cystitis occurring after administration of nivolumab, an anti-programmed death-1 antibody, which was considered to be an immune-related adverse event, is reported. A 62-year-old man with pulmonary squamous cell carcinoma (T4N0M1a Stage IV) was being treated with nivolumab as fourth-line ch...
Gespeichert in:
| Veröffentlicht in: | International cancer conference journal 2017-10, Vol.6 (4), p.164-166 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 166 |
|---|---|
| container_issue | 4 |
| container_start_page | 164 |
| container_title | International cancer conference journal |
| container_volume | 6 |
| creator | Ozaki, Keisuke Takahashi, Hisaya Murakami, Yoshihide Kiyoku, Hiroshi Kanayama, Hiroomi |
| description | A case of cystitis occurring after administration of nivolumab, an anti-programmed death-1 antibody, which was considered to be an immune-related adverse event, is reported. A 62-year-old man with pulmonary squamous cell carcinoma (T4N0M1a Stage IV) was being treated with nivolumab as fourth-line chemotherapy. He was hospitalized for a fever and diarrhea after 3 courses. Fasting and antibiotic medication reduced the fever and alleviated the diarrhea. He then developed cystitis with no evidence of infection. Cystoscopy showed diffused redness and erosion of the bladder mucosa; urine cytology was negative. Imaging examinations showed no abnormalities. Urinary tract pain and hematuria due to nivolumab were diagnosed by exclusion following a bladder biopsy. Since symptomatic treatment was unsuccessful, steroid pulse therapy was given, which resolved the patient’s signs and symptoms. The patient was then switched to maintenance prednisolone and tapered gradually. The 4th course of nivolumab was then resumed with concomitant administration of steroid, and it was possible to continue administration of nivolumab without progression of cystitis. |
| doi_str_mv | 10.1007/s13691-017-0298-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6498356</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2919607277</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-60264253568244678e65623518a9614ca80ab56f591ffd498d6eed886f8737063</originalsourceid><addsrcrecordid>eNp1kEtLAzEUhYMottT-ADcy4Ho0r8ljI5TiCwpudB3SmaSmdCY1mSn035thaq0LyeIG7rnfORwArhG8QxDy-4gIkyiHiOcQS5GzMzDGSOKcIEHOT_4jMI1xDSHEkEoo2CUYEYSoTG8M6CwrdTSZt1m5j61rXcy0bU3IdFW7xsU26Nb5phc0buc3Xa2XV-DC6k0008OcgI-nx_f5S754e36dzxZ5SSRqcwYxo7ggBROYUsaFYQXDpEBCS4ZoqQXUy4LZQiJrKypFxYyphGBWcMIhIxPwMHC33bI2VWmalGajtsHVOuyV10793TTuU638TrEES7YJcHsABP_Vmdiqte9CkzIrLJFkkGPOkwoNqjL4GIOxRwcEVd-1GrpWqWvVd6168s1ptOPFT7NJgAdBTKtmZcKv9f_Ub0C2h_8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2919607277</pqid></control><display><type>article</type><title>A case of cystitis after administration of nivolumab</title><source>ProQuest Central (Alumni Edition)</source><source>Springer Online Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>PubMed Central</source><source>ProQuest Central</source><creator>Ozaki, Keisuke ; Takahashi, Hisaya ; Murakami, Yoshihide ; Kiyoku, Hiroshi ; Kanayama, Hiroomi</creator><creatorcontrib>Ozaki, Keisuke ; Takahashi, Hisaya ; Murakami, Yoshihide ; Kiyoku, Hiroshi ; Kanayama, Hiroomi</creatorcontrib><description>A case of cystitis occurring after administration of nivolumab, an anti-programmed death-1 antibody, which was considered to be an immune-related adverse event, is reported. A 62-year-old man with pulmonary squamous cell carcinoma (T4N0M1a Stage IV) was being treated with nivolumab as fourth-line chemotherapy. He was hospitalized for a fever and diarrhea after 3 courses. Fasting and antibiotic medication reduced the fever and alleviated the diarrhea. He then developed cystitis with no evidence of infection. Cystoscopy showed diffused redness and erosion of the bladder mucosa; urine cytology was negative. Imaging examinations showed no abnormalities. Urinary tract pain and hematuria due to nivolumab were diagnosed by exclusion following a bladder biopsy. Since symptomatic treatment was unsuccessful, steroid pulse therapy was given, which resolved the patient’s signs and symptoms. The patient was then switched to maintenance prednisolone and tapered gradually. The 4th course of nivolumab was then resumed with concomitant administration of steroid, and it was possible to continue administration of nivolumab without progression of cystitis.</description><identifier>ISSN: 2192-3183</identifier><identifier>EISSN: 2192-3183</identifier><identifier>DOI: 10.1007/s13691-017-0298-6</identifier><identifier>PMID: 31149494</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Antibodies ; Apoptosis ; Biopsy ; Bladder ; Cancer therapies ; Case Report ; Chemotherapy ; Collaboration ; Cystitis ; Cytology ; Diarrhea ; Drug dosages ; Fever ; Hematuria ; Lung cancer ; Lung carcinoma ; Medicine ; Medicine & Public Health ; Melanoma ; Oncology ; Prednisolone ; Skin cancer ; Squamous cell carcinoma ; Steroids ; Surgical Oncology ; Tumors ; Urinary tract ; Urination ; Urogenital system</subject><ispartof>International cancer conference journal, 2017-10, Vol.6 (4), p.164-166</ispartof><rights>The Japan Society of Clinical Oncology 2017</rights><rights>The Japan Society of Clinical Oncology 2017.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-60264253568244678e65623518a9614ca80ab56f591ffd498d6eed886f8737063</citedby><cites>FETCH-LOGICAL-c391t-60264253568244678e65623518a9614ca80ab56f591ffd498d6eed886f8737063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498356/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2919607277?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,21393,21394,27929,27930,33535,33749,41493,42562,43664,43810,51324,53796,53798,64390,64394,72474</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31149494$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ozaki, Keisuke</creatorcontrib><creatorcontrib>Takahashi, Hisaya</creatorcontrib><creatorcontrib>Murakami, Yoshihide</creatorcontrib><creatorcontrib>Kiyoku, Hiroshi</creatorcontrib><creatorcontrib>Kanayama, Hiroomi</creatorcontrib><title>A case of cystitis after administration of nivolumab</title><title>International cancer conference journal</title><addtitle>Int Canc Conf J</addtitle><addtitle>Int Cancer Conf J</addtitle><description>A case of cystitis occurring after administration of nivolumab, an anti-programmed death-1 antibody, which was considered to be an immune-related adverse event, is reported. A 62-year-old man with pulmonary squamous cell carcinoma (T4N0M1a Stage IV) was being treated with nivolumab as fourth-line chemotherapy. He was hospitalized for a fever and diarrhea after 3 courses. Fasting and antibiotic medication reduced the fever and alleviated the diarrhea. He then developed cystitis with no evidence of infection. Cystoscopy showed diffused redness and erosion of the bladder mucosa; urine cytology was negative. Imaging examinations showed no abnormalities. Urinary tract pain and hematuria due to nivolumab were diagnosed by exclusion following a bladder biopsy. Since symptomatic treatment was unsuccessful, steroid pulse therapy was given, which resolved the patient’s signs and symptoms. The patient was then switched to maintenance prednisolone and tapered gradually. The 4th course of nivolumab was then resumed with concomitant administration of steroid, and it was possible to continue administration of nivolumab without progression of cystitis.</description><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Biopsy</subject><subject>Bladder</subject><subject>Cancer therapies</subject><subject>Case Report</subject><subject>Chemotherapy</subject><subject>Collaboration</subject><subject>Cystitis</subject><subject>Cytology</subject><subject>Diarrhea</subject><subject>Drug dosages</subject><subject>Fever</subject><subject>Hematuria</subject><subject>Lung cancer</subject><subject>Lung carcinoma</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melanoma</subject><subject>Oncology</subject><subject>Prednisolone</subject><subject>Skin cancer</subject><subject>Squamous cell carcinoma</subject><subject>Steroids</subject><subject>Surgical Oncology</subject><subject>Tumors</subject><subject>Urinary tract</subject><subject>Urination</subject><subject>Urogenital system</subject><issn>2192-3183</issn><issn>2192-3183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kEtLAzEUhYMottT-ADcy4Ho0r8ljI5TiCwpudB3SmaSmdCY1mSn035thaq0LyeIG7rnfORwArhG8QxDy-4gIkyiHiOcQS5GzMzDGSOKcIEHOT_4jMI1xDSHEkEoo2CUYEYSoTG8M6CwrdTSZt1m5j61rXcy0bU3IdFW7xsU26Nb5phc0buc3Xa2XV-DC6k0008OcgI-nx_f5S754e36dzxZ5SSRqcwYxo7ggBROYUsaFYQXDpEBCS4ZoqQXUy4LZQiJrKypFxYyphGBWcMIhIxPwMHC33bI2VWmalGajtsHVOuyV10793TTuU638TrEES7YJcHsABP_Vmdiqte9CkzIrLJFkkGPOkwoNqjL4GIOxRwcEVd-1GrpWqWvVd6168s1ptOPFT7NJgAdBTKtmZcKv9f_Ub0C2h_8</recordid><startdate>20171001</startdate><enddate>20171001</enddate><creator>Ozaki, Keisuke</creator><creator>Takahashi, Hisaya</creator><creator>Murakami, Yoshihide</creator><creator>Kiyoku, Hiroshi</creator><creator>Kanayama, Hiroomi</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20171001</creationdate><title>A case of cystitis after administration of nivolumab</title><author>Ozaki, Keisuke ; Takahashi, Hisaya ; Murakami, Yoshihide ; Kiyoku, Hiroshi ; Kanayama, Hiroomi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-60264253568244678e65623518a9614ca80ab56f591ffd498d6eed886f8737063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Biopsy</topic><topic>Bladder</topic><topic>Cancer therapies</topic><topic>Case Report</topic><topic>Chemotherapy</topic><topic>Collaboration</topic><topic>Cystitis</topic><topic>Cytology</topic><topic>Diarrhea</topic><topic>Drug dosages</topic><topic>Fever</topic><topic>Hematuria</topic><topic>Lung cancer</topic><topic>Lung carcinoma</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melanoma</topic><topic>Oncology</topic><topic>Prednisolone</topic><topic>Skin cancer</topic><topic>Squamous cell carcinoma</topic><topic>Steroids</topic><topic>Surgical Oncology</topic><topic>Tumors</topic><topic>Urinary tract</topic><topic>Urination</topic><topic>Urogenital system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ozaki, Keisuke</creatorcontrib><creatorcontrib>Takahashi, Hisaya</creatorcontrib><creatorcontrib>Murakami, Yoshihide</creatorcontrib><creatorcontrib>Kiyoku, Hiroshi</creatorcontrib><creatorcontrib>Kanayama, Hiroomi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International cancer conference journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ozaki, Keisuke</au><au>Takahashi, Hisaya</au><au>Murakami, Yoshihide</au><au>Kiyoku, Hiroshi</au><au>Kanayama, Hiroomi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case of cystitis after administration of nivolumab</atitle><jtitle>International cancer conference journal</jtitle><stitle>Int Canc Conf J</stitle><addtitle>Int Cancer Conf J</addtitle><date>2017-10-01</date><risdate>2017</risdate><volume>6</volume><issue>4</issue><spage>164</spage><epage>166</epage><pages>164-166</pages><issn>2192-3183</issn><eissn>2192-3183</eissn><abstract>A case of cystitis occurring after administration of nivolumab, an anti-programmed death-1 antibody, which was considered to be an immune-related adverse event, is reported. A 62-year-old man with pulmonary squamous cell carcinoma (T4N0M1a Stage IV) was being treated with nivolumab as fourth-line chemotherapy. He was hospitalized for a fever and diarrhea after 3 courses. Fasting and antibiotic medication reduced the fever and alleviated the diarrhea. He then developed cystitis with no evidence of infection. Cystoscopy showed diffused redness and erosion of the bladder mucosa; urine cytology was negative. Imaging examinations showed no abnormalities. Urinary tract pain and hematuria due to nivolumab were diagnosed by exclusion following a bladder biopsy. Since symptomatic treatment was unsuccessful, steroid pulse therapy was given, which resolved the patient’s signs and symptoms. The patient was then switched to maintenance prednisolone and tapered gradually. The 4th course of nivolumab was then resumed with concomitant administration of steroid, and it was possible to continue administration of nivolumab without progression of cystitis.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>31149494</pmid><doi>10.1007/s13691-017-0298-6</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2192-3183 |
| ispartof | International cancer conference journal, 2017-10, Vol.6 (4), p.164-166 |
| issn | 2192-3183 2192-3183 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6498356 |
| source | ProQuest Central (Alumni Edition); Springer Online Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; PubMed Central; ProQuest Central |
| subjects | Antibodies Apoptosis Biopsy Bladder Cancer therapies Case Report Chemotherapy Collaboration Cystitis Cytology Diarrhea Drug dosages Fever Hematuria Lung cancer Lung carcinoma Medicine Medicine & Public Health Melanoma Oncology Prednisolone Skin cancer Squamous cell carcinoma Steroids Surgical Oncology Tumors Urinary tract Urination Urogenital system |
| title | A case of cystitis after administration of nivolumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T05%3A00%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case%20of%20cystitis%20after%20administration%20of%20nivolumab&rft.jtitle=International%20cancer%20conference%20journal&rft.au=Ozaki,%20Keisuke&rft.date=2017-10-01&rft.volume=6&rft.issue=4&rft.spage=164&rft.epage=166&rft.pages=164-166&rft.issn=2192-3183&rft.eissn=2192-3183&rft_id=info:doi/10.1007/s13691-017-0298-6&rft_dat=%3Cproquest_pubme%3E2919607277%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2919607277&rft_id=info:pmid/31149494&rfr_iscdi=true |